Advanced Accelerator Applications SA
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
7
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Sultone compound derivatives substituted by nucleophiles, in particular radionuclides, and use thereof for marking macromolecules (US 9,051,292) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Stable, concentrated radionuclide complex solutions (US 11,904,027) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 2 fees due Sep 24, 2027
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,268,594 | pyrC as a selection marker in Escherichia coli In force · From the USPTO record | In force | From the USPTO record | |
| US 8,388,972 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma In force · From the USPTO record | In force | From the USPTO record | |
| US 8,741,850 | Compounds modulators of VEGF activity and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,737,622 | Compounds modulators of VEGF activity and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,546,526 | Selective Alfavbeta3 Receptor Peptide Antagonist for Therapeutic and Diagnostic Applications In force · High confidence | In force | High confidence | |
| US 9,017,938 | Use of MICRORNA-199B-5P in Medical and Diagnostic Field In force · High confidence | In force | High confidence | |
| US 9,051,292 | Sultone compound derivatives substituted by nucleophiles, in particular radionuclides, and use thereof for marking macromolecules In force · From the USPTO record | In force | From the USPTO record | |
| US 9,839,703 | Radiolabeled Grpr-Antagonists for Diagnostic Imaging and Treatment of Grpr-Positive Cancer In force · High confidence | In force | High confidence | |
| US 9,611,215 | Nucleophile-reactive sulfonated compounds for the (radio)labelling of (bio) molecules; precursors and conjugates thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,196,421 | Nucleophile-reactive sulfonated compounds for the (radio)labelling of (bio)molecules; precursors and conjugates thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 21: 2 patents in force now held by others · 1 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 3 abandoned · 3 no status recorded